Vladimir Makarov
YOU?
Author Swipe
View article: Peculiarities of the intrinsic symmetry of linear and nonlinear optical susceptibility tensors in nonabsorbing inhomogeneous media with nonlocality of optical response
Peculiarities of the intrinsic symmetry of linear and nonlinear optical susceptibility tensors in nonabsorbing inhomogeneous media with nonlocality of optical response Open
We show that using the Landau–Lifshitz form of the constitutive equations to construct electrodynamics of inhomogeneous nonabsorbing media with nonlocality of optical response leads to previously unknown intrinsic symmetry relations of the…
View article: Patient-Derived Free-Floating Non-Small Cell Lung Cancer Organoids: A Versatile Tool for Personalized Testing of Chemotherapeutic Drugs
Patient-Derived Free-Floating Non-Small Cell Lung Cancer Organoids: A Versatile Tool for Personalized Testing of Chemotherapeutic Drugs Open
Patient-derived tumor organoids (PDTOs) are a novel preclinical model of non-small cell lung cancer (NSCLC) for studying tumor biology and precision medicine, which recapitulates tumor morphology and gene expression profile. However, some …
View article: Methodology development for creating energy-efficient fans for air cooling devices
Methodology development for creating energy-efficient fans for air cooling devices Open
Introduction. Increasing the competitiveness of enterprises in the mining and oil and gas sectors of the Russian economy in combination with industrial safety requirements actualizes the task of developing a methodology for creating energy…
View article: Patient-Derived Free-Floating Non-Small Cell Lung Cancer Organoids: A Versatile Tool for Personalized Testing of Chemotherapeutic Drugs
Patient-Derived Free-Floating Non-Small Cell Lung Cancer Organoids: A Versatile Tool for Personalized Testing of Chemotherapeutic Drugs Open
Patient-derived tumor organoids (PDTOs) are a novel preclinical model of non-small cell lung cancer (NSCLC) for studying tumor biology and precision medicine, which recapitulates tumor morphology and gene expression profile. However, some …
View article: Mathematical Modeling of Non-Small-Cell Lung Cancer Biology through the Experimental Data on Cell Composition and Growth of Patient-Derived Organoids
Mathematical Modeling of Non-Small-Cell Lung Cancer Biology through the Experimental Data on Cell Composition and Growth of Patient-Derived Organoids Open
Mathematical models of non-small-cell lung cancer are powerful tools that use clinical and experimental data to describe various aspects of tumorigenesis. The developed algorithms capture phenotypic changes in the tumor and predict changes…
View article: Mathematical Modeling of Non-small Cell Lung Cancer Biology Through the Experimental Data on Cell Composition and Growth of Patient-Derived Organoids
Mathematical Modeling of Non-small Cell Lung Cancer Biology Through the Experimental Data on Cell Composition and Growth of Patient-Derived Organoids Open
Mathematical models of non-small cell lung cancer are powerful tools that use clinical and experimental data to describe various aspects of tumorigenesis. The developed algorithms capture phenotypic changes in the tumor and predict changes…
View article: Figure S2 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S2 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Pan-AKT inhibitor treatment of XTC.UC1 cells does not result in large decreases in proliferation. A, Comparison of MK2206 treatment in NTHY-ori (top) and XTC.UC1 (bottom) cells. B, Immunoblot analysis of mTOR signaling in NTHY-ori and XTC.…
View article: Supplementary Data 1 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Supplementary Data 1 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab Open
Mutation annotation file (MAF) showing all nonsynonymous exonic mutations identified in the lenvatinib/pembrolizumab cohort.
View article: Figure S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Somatic genomic mutations in XTC.UC1 and HCC. Significantly mutated genes, as determined by the MutSig algorithm are shown. Left: overall count for each gene. Right: gene list.
View article: Data from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Data from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy Open
Targeted inhibition of BRAF V600E achieves tumor control in a subset of advanced thyroid tumors. Nearly all tumors develop resistance, and some have been observed to subsequently undergo dedifferentiation. The molecular alterations associa…
View article: Figure S3 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S3 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
mTOR inhibitor treatment suppresses XTC.UC1 cell proliferation in vitro. Comparison of dose response of three mTOR inhibitors rapamycin, AZD8055 and AZD2014 in XTC.UC1 cells with 16-day-treatment.
View article: Supplementary Data 2 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Supplementary Data 2 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab Open
HLA class-I allele data along with mean HED values for the lenvatinib/pembrolizumab and MSK-IMPACT cohorts.
View article: Supplementary Data 2 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Supplementary Data 2 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab Open
HLA class-I allele data along with mean HED values for the lenvatinib/pembrolizumab and MSK-IMPACT cohorts.
View article: Data from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Data from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Hurthle cell carcinomas (HCCs) are refractory to radioactive iodine and unresponsive to chemotherapeutic agents, with a fatality rate that is the highest among all types of thyroid cancer after anaplastic thyroid cancer. Our previous study…
View article: Figure S5 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S5 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Combination treatment with rapamycin and lenvatinib in PDX model TC1m1. A, Combination treatment resulted in enhanced decrease in CD31 staining endothelial vessels compared to lenvatinib alone or rapamycin alone. B, The average IMVD values…
View article: Supplemental Tables 1-5 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Supplemental Tables 1-5 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy Open
Supplemental Table 1. Genomic alterations observed in MSK-THY1 Supplemental Table 2. Cellular prevalence of single nucleotide variants in MSK-THY Supplemental Table 3. Normalized gene expression data from patient MSK-THY1 Supplemental Tabl…
View article: Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab Open
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have …
View article: Figure S4 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S4 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
A, Combination treatment of XTC.UC1 with rapamycin and the pan-AKT inhibitor MK2206 and MEK inhibitor PD325902. B, Cell proliferation assay of XTC.UC1 cells treated with rapamycin or AZD8055 alone and in combination with MK2206 or PD325902…
View article: Table S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Table S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Quantitative RT-PCR primer sequences
View article: Figure S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Somatic genomic mutations in XTC.UC1 and HCC. Significantly mutated genes, as determined by the MutSig algorithm are shown. Left: overall count for each gene. Right: gene list.
View article: Figure S3 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S3 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
mTOR inhibitor treatment suppresses XTC.UC1 cell proliferation in vitro. Comparison of dose response of three mTOR inhibitors rapamycin, AZD8055 and AZD2014 in XTC.UC1 cells with 16-day-treatment.
View article: Supplemental Tables 1-5 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Supplemental Tables 1-5 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy Open
Supplemental Table 1. Genomic alterations observed in MSK-THY1 Supplemental Table 2. Cellular prevalence of single nucleotide variants in MSK-THY Supplemental Table 3. Normalized gene expression data from patient MSK-THY1 Supplemental Tabl…
View article: Supplemental Figures 1-6 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Supplemental Figures 1-6 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy Open
Supplemental Figure 1. Increased clonal heterogeneity in anaplastic metastases (ATC Met 1, 5 clones Supplemental Figure 2. Copy-number alterations for the pre-vemurafenib papillary thyroid carcinoma sample Supplemental Figure 3. Differenti…
View article: Figure S4 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S4 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
A, Combination treatment of XTC.UC1 with rapamycin and the pan-AKT inhibitor MK2206 and MEK inhibitor PD325902. B, Cell proliferation assay of XTC.UC1 cells treated with rapamycin or AZD8055 alone and in combination with MK2206 or PD325902…
View article: Table S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Table S1 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Quantitative RT-PCR primer sequences
View article: Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Data from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab Open
Immune checkpoint blockade (ICB) therapy has substantially improved the outcomes of patients with many types of cancers, including renal cell carcinoma (RCC). Initially studied as monotherapy, immunotherapy-based combination regimens have …
View article: Figure S5 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Figure S5 from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Combination treatment with rapamycin and lenvatinib in PDX model TC1m1. A, Combination treatment resulted in enhanced decrease in CD31 staining endothelial vessels compared to lenvatinib alone or rapamycin alone. B, The average IMVD values…
View article: Supplemental Figures 1-6 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy
Supplemental Figures 1-6 from Genomic and Transcriptomic Correlates of Thyroid Carcinoma Evolution after BRAF Inhibitor Therapy Open
Supplemental Figure 1. Increased clonal heterogeneity in anaplastic metastases (ATC Met 1, 5 clones Supplemental Figure 2. Copy-number alterations for the pre-vemurafenib papillary thyroid carcinoma sample Supplemental Figure 3. Differenti…
View article: Supplementary Data 1 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab
Supplementary Data 1 from High Response Rate and Durability Driven by HLA Genetic Diversity in Patients with Kidney Cancer Treated with Lenvatinib and Pembrolizumab Open
Mutation annotation file (MAF) showing all nonsynonymous exonic mutations identified in the lenvatinib/pembrolizumab cohort.
View article: Data from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity
Data from Targeting the mTOR Pathway in Hurthle Cell Carcinoma Results in Potent Antitumor Activity Open
Hurthle cell carcinomas (HCCs) are refractory to radioactive iodine and unresponsive to chemotherapeutic agents, with a fatality rate that is the highest among all types of thyroid cancer after anaplastic thyroid cancer. Our previous study…